Dragged down by negative returns for shares of NVIDIA Corp. and Amgen, the Dow Jones Industrial Average is in a selloff Wednesday afternoon. The Dow was most recently trading 589 points lower (-1.5%), ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Pharmaceutical company Sandoz has filed a federal lawsuit accusing Amgen of orchestrating an illegal scheme to block biosimilar competition for its blockbuster arthritis drug Enbrel, resulting in ...

After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...

Swiss generic and biosimilar medicines firm Sandoz (SIX: SDZ) today announced it has filed an antitrust lawsuit in the USA ...

The planned spin-off of Holcim's North American business should take place in June, subject to the approval of shareholders ...

A Delaware federal court has ruled against Amgen's bid to dismiss an antitrust lawsuit filed by Regeneron Pharmaceuticals Inc ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

In the world of chemistry, some reactions are too slow or too difficult and require the assistance of metals that act as ...

Advances Amgen’s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, CA, USA I April 3, 2025 I Amgen (NASDAQ:AMGN) ...